Half-year report · HY
4548.TEDINET S100X22N
Period2025-04-01 → 2025-09-30
Filed2025-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥17.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥39.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥20.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | −¥557m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥2.5bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥531m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.9bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥361m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.4bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥229m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.2bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.9bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥229m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥1.9bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥81.9bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥83.9bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥84.4bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥9.7bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥10.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥72.2bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥73.2bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥75.3bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.1bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥15.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥12.3bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥19.8bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥1.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥3.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥838m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥732m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥4.21 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.25 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.39 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 88.2% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.3% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.2% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| LALreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.8bn |
| LALreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.8bn |
| LALreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥178m |
| Pharmaceuticalreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥12.1bn |
| Pharmaceuticalreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥12.1bn |
| Pharmaceuticalreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥735m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥17.9bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥17.9bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | −¥557m |
| LALreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.9bn |
| LALreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.9bn |
| LALreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥481m |
| Pharmaceuticalreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥14.3bn |
| Pharmaceuticalreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥14.3bn |
| Pharmaceuticalreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.1bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥20.2bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥20.2bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥2.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 528
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from sales of investment securities inv cf | Prior1InterimDuration | 1000000 | JPY |
| Proceeds from sales of investment securities inv cf | InterimDuration | 879000000 | JPY |
| Other net inv cf | Prior1InterimDuration | -0 | JPY |
| Other net inv cf | InterimDuration | 0 | JPY |
| Net cash provided by used in investment activities | Prior1InterimDuration | -1397000000 | JPY |
| Net cash provided by used in investment activities | InterimDuration | -3572000000 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | -709000000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -818000000 | JPY |
| Repayments of lease obligations fin cf | Prior1InterimDuration | -25000000 | JPY |
| Repayments of lease obligations fin cf | InterimDuration | -20000000 | JPY |
| Other net fin cf | Prior1InterimDuration | 2000000 | JPY |
| Other net fin cf | InterimDuration | 0 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | -732000000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | -838000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | 243000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | -250000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | 1109000000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | -5987000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 18701000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 18322000000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 19810000000 | JPY |
| Cash and cash equivalents | InterimInstant | 12335000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00970-000PharmaceuticalReportableSegmentsMember | 14347000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00970-000LALReportableSegmentsMember | 5863000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 20210000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 20210000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00970-000PharmaceuticalReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00970-000LALReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00970-000PharmaceuticalReportableSegmentsMember | 14347000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00970-000LALReportableSegmentsMember | 5863000000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 20210000000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1InterimDuration | 20210000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00970-000PharmaceuticalReportableSegmentsMember | 2056000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00970-000LALReportableSegmentsMember | 481000000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | 2537000000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1InterimDuration | 2537000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00970-000PharmaceuticalReportableSegmentsMember | 12130000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00970-000LALReportableSegmentsMember | 5779000000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 17910000000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 17910000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00970-000PharmaceuticalReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00970-000LALReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_ReportableSegmentsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |